Tiziana Reports Consistent Brain Inflammation Reduction in Third MSA Patient Treated with Intranasal Foralumab

summarizeSummary

Tiziana announced PET imaging results from the third MSA patient in its Phase 2 trial of intranasal foralumab, showing up to a 34% reduction in brain inflammation—consistent with the first two patients. The reproducible signal supports the drug's potential in a disease with no approved therapies.

check_boxKey Events · Product Development and Regulatory · TLSA

• Third MSA Patient Shows Consistent Inflammation Reduction

  Quantitative PET imaging revealed up to a 34% reduction in SUV and a 26% reduction in SUVR in the basal ganglia and cerebellar white matter, closely matching the ~35% SUV and 24% SUVR reductions seen in the first two patients.

• Reproducible Signal Across Patients

  The consistency of PET findings across three patients reinforces evidence of biological activity for intranasal foralumab in dampening neuroinflammation in MSA, a disease with no approved disease-modifying treatments.

• Next Steps: Further Validation Planned

  Tiziana plans to continue evaluating intranasal foralumab in additional patients to further validate these findings and better characterize the therapy's potential in MSA.

auto_awesomeAnalysis · TLSA · Life Sciences

The third MSA patient demonstrated up to a 34% reduction in neuroinflammation on PET imaging, closely mirroring the ~35% and 24% reductions observed in the first two patients. Reproducibility across patients strengthens the case that intranasal foralumab has real biological activity in a disease with no approved treatments. While this is early-stage data, consistency is what moves a clinical program from 'interesting signal' to 'potentially real drug.'